NTLA

Intellia Therapeutics
NTLA

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$990.26M
EV
$402.41M
Shares Outstanding
103.58M
Beta
2.21

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$37.30
P/E 2025E
-
P/Revenue 2025E
17.67x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Intellia Therapeutics, Inc.

gainify
NTLA

Intellia Therapeutics, Inc.

NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment...

Sector

Healthcare

Industry

Biotechnology

CEO

Leonard, John

Employees

403

IPO Date

2016-05-06

Headquarters

40 Erie Street, Suite 130, Cambridge, Massachusetts, 02139, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.